{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-036811","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.359334+00:00","generated_at":"2026-06-04T07:07:06.812594+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aura Biosciences reports FY2023 net loss $76.4M; Phase 3 CoMpass trial enrolling with FDA SPA","bullets":["Cash and equivalents $226.2M as of Dec 31, 2023; expected to fund operations into H2 2026.","Net loss $22.1M Q4 2023 and $76.4M full year 2023 vs $16.6M and $58.8M prior year.","R&D expenses $65.2M for FY2023, up from $42.2M due to Phase 3 start and manufacturing costs.","Global Phase 3 CoMpass trial for small choroidal melanoma actively enrolling under FDA SPA; Phase 2 showed 80% tumor control, 90% vision preservation.","Phase 1 bladder cancer trial ongoing; data expected mid-2024; first patient showed complete response after single dose with light activation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-036811","json":"https://secwatch.observer/filing/0000950170-24-036811.json","markdown":"https://secwatch.observer/filing/0000950170-24-036811.md","text":"https://secwatch.observer/filing/0000950170-24-036811.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017024036811/0000950170-24-036811-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017024036811/aura-20240327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:07:06.812594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4c0f18d88e11d6a6157cd522641d22de699fb6f","claim":"Aura Biosciences, Inc. reported financial results for fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On March 27, 2024, Aura Biosciences, Inc., issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017024036811/0000950170-24-036811-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}